GSK says Dovato was as effective as Biktarvy in head-to-head HIV trial — but patients gained less weight
GSK’s ViiV said its two-drug HIV regimen Dovato was just as effective as Gilead’s three-drug combo Biktarvy in what it says is the largest head …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
